The place of aceclofenac in the preparation of patients with rheumatic diseases for joint surgery
https://doi.org/10.14412/1996-7012-2019-4-124-129
Abstract
To identify risk factors for gastrointestinal, cardiovascular, and thrombotic complications, as well as postoperative bleeding, by individually choosing analgesic anti-inflammatory therapy, including that with nonsteroidal anti-inflammatory drugs, is the most important task in the preoperative preparation of patients with rheumatic inflammatory joint diseases.
The paper reviews studies evaluating the efficiency and safety of long-term aceclofenac use in patients who are to undergo joint surgery.
About the Authors
V. N. Amirdzhanova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Vera Nikolaevna Amirdzhanova
34A, Kashirskoe Shosse, Moscow 115522
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for doctors]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.
2. Carpintero P, Caeiro JR, Carpintero R, et al. Complications of hip fractures: A review. World J Orthop. 2014 Sep 18; 5(4):402-11. doi: 10.5312/wjo.v5.i4.402. eCollection 2014.
3. Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015; 9(1): 4-24. (In Russ.) doi: 10. 14412/1996-7012-2015-1-4-23
4. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis - an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19; 13: 55. doi: 10.1186/s12916-015-0285-8.
5. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.
6. Lemmel E, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53.
7. Peris F, Bird H, Serni U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a metaanalysis. Eur J Rheumatol Inflamm.1996;(16):37-45.
8. Willoughby D, Moore A, Colville-Nash P. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000 Feb 19;355(9204):646-8.
9. Saraf S. Aceclofenac: A Potent NonSteroidal Anti-Inflammatory Drug. In Latest Reviews 2006; 4(3):119-24.
10. Hinz B, Rau T, Augel D, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
11. Nasonova VA, Karateev AE. Symptomatic therapy for pain in rheumatic diseases: a place of aceclofenac. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009;3(3):58-65. (In Russ.). doi: 10.14412/1996-7012-2009-560
12. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.
13. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.
14. Presser Lima PV, Fontanella V. Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. Int J Oral Maxillofac Surg. 2006 Jun;35(6):518-21.
15. Nasonov EL Specific COX-2 inhibitors: solved and unsolved problems. Klinicheskaya farmakologiya i terapiya. 2000;(1):57-64. (In Russ.).
16. Vane J, Botting R. Mechanism of action in nonsteroidal anti-inflammatori drugs. Am J Med. 1998 Mar 30;104(3A):2S-8S; discussion 21S-22S.
17. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.
18. Henrotin Y, De Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001 Aug;50(8):391-9.
19. Huskisson E, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Europ J Rheumatol Inflamm. 2000; 7(1):1-7.
20. Lanas A, Garsia-Rodriguez L, Arroyo M, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-steroidal nonaspirin NSAID, aspirin, and combinations. Gut. 2006 Dec;55(12):1731-8. Epub 2006 May 10.
21. Laporte J, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411-20.
22. Llorente Melero MJ, Tenias Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual nonsteroidal anti-inflammatory drugs. Rev Esp Enferm Dig. 2002 Jan; 94(1):7-18.
23. Raber A, Heras J, Costa J, et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag. 2007 Jun;3(2):225-30.
24. Karateev AE. Results of the clinical study AEROPLAN (analysis of the effectiveness and risk of complications in the treatment of arthritis with aceclofenac and nimesulide). Consilium Medicum. 2013;15(2): 48-53. (In Russ.).
25. Karateev AE. Aceclofenac in rheumatology: The golden mean. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(2):88-94. (In Russ.). doi: 10.14412/1996-7012-2013-2389
26. Huskisson EC. Aceclofenac: Ace or just another Jack? Europ J Rheum Inform. 1996; 16(1):1-2.
27. Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national casecontrol study from Finland. Eur Heart J. 2006 Jul;27(14):1657-63. Epub 2006 May 26.
28. Wood SG, Fitzpatrik K, et al. Pharmacokinetics and metabolism a new NSAID/analgesic aceclofenac in man. Pharm Res. 1990;7(9):212.
29. Lila AM. The use of Aertal (aceclofenac) in clinical practice. Russkii meditsinskii zhurnal. 2009;17(4): 291-4. (In Russ.).
30. Lila AM. The use of Aertal in rheumatological practice. Spravochnik poliklinicheskogo vracha. 2010;(8):47-9. (In Russ.).
31. Nasonova VA. Aceclofenac-safety and efficacy. Russkii meditsinskii zhurnal. 2003; 11(5):3-6. (In Russ.).
32. Singh G, Graham D, Wang H, et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65(Suppl. II):61.
33. Ashikhmin YaI, Drapkina OM. Pain syndrome treatment from the position of efficiency and safety. Effektivnaya farmakoterapiya. Revmatologiya. Travmatologiya. Ortopediya. 2011;(1):38-43. (In Russ.).
Review
For citations:
Amirdzhanova VN, Karateev AE. The place of aceclofenac in the preparation of patients with rheumatic diseases for joint surgery. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(4):124-129. (In Russ.) https://doi.org/10.14412/1996-7012-2019-4-124-129
Views:
537
Email this article 